Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

NCT06238817 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT06238817
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06238817 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
Lead sponsor
Incyte Corporation
Phase
Phase 3
Overall status
Completed
Start date
April 26, 2024
Completion date
October 17, 2025
Enrollment
241 (actual)
Sites
94

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis